CBP-1018

CBP-1018 is a first-in-class bi-ligand-drug conjugate designed to target both prostate specific membrane antigen (PSMA) and folate receptor alpha (FRα), which are overexpressed in various solid tumors including prostate, renal, lung, ovarian, breast, and pancreatic cancers. The drug utilizes monomethyl auristatin E (MMAE), a potent tubulin inhibitor, as its cytotoxic payload. By binding simultaneously to PSMA and FRα on tumor cells or angiogenic endothelial cells, CBP-1018 delivers MMAE directly into the cancer cells with high specificity and efficiency. This targeted approach aims to maximize antitumor activity while minimizing off-target toxicity. Preclinical studies have demonstrated strong antitumor effects across multiple xenograft models with up to 96% tumor growth inhibition. Clinical trials have shown promising safety and efficacy profiles in patients with advanced solid tumors—especially metastatic castration-resistant prostate cancer (mCRPC)—with manageable adverse events primarily hematologic in nature. The drug is being developed by Coherent Biopharma using their proprietary Bi-XDC technology platform[1][2][4][5][6].